WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001083472) MUSCARINIC AGONISTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/083472    International Application No.:    PCT/US2001/013561
Publication Date: 08.11.2001 International Filing Date: 27.04.2001
Chapter 2 Demand Filed:    28.11.2001    
IPC:
C07D 401/06 (2006.01), C07D 405/06 (2006.01), C07D 409/06 (2006.01), C07D 413/06 (2006.01), C07D 417/06 (2006.01), C07D 471/04 (2006.01)
Applicants: ACADIA PHARMACEUTICALS, INC. [US/US]; 3911 Sorrento Valley Boulevard San Diego, CA 92121 (US) (For All Designated States Except US).
ANDERSSON, Carl-Magnus, A. [SE/DK]; (DK) (For US Only).
FRIBERG, Bo, Lennart, M. [SE/DK]; (US) (For US Only).
SKJAERBAEK, Niels [DK/DK]; (DK) (For US Only).
SPALDING, Tracy [GB/US]; (US) (For US Only).
ULDAM, Allan, K. [DK/DK]; (DK) (For US Only)
Inventors: ANDERSSON, Carl-Magnus, A.; (DK).
FRIBERG, Bo, Lennart, M.; (US).
SKJAERBAEK, Niels; (DK).
SPALDING, Tracy; (US).
ULDAM, Allan, K.; (DK)
Agent: BABIN, Jane, K.; Pillsbury Winthrop LLP 50 Fremont Street San Francisco, CA 94105 (US).
VOSSIUS & PARTNER; Siebertsrasse 4 81675 Munich (DE)
Priority Data:
60/200,791 28.04.2000 US
Title (EN) MUSCARINIC AGONISTS
(FR) AGONISTES MUSCARINIQUES
Abstract: front page image
(EN)Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.
(FR)L'invention concerne des composés et des méthodes destinés au traitement d'états pathologiques dans lesquels une modification de l'activité du récepteur cholinergique, spécialement le récepteur muscarinique m1, m4 ou m1 et m4, a un effet bénéfique. Selon la méthode, une dose efficace d'un composé est administrée à un patient pour lequel un tel traitement est nécessaire.
Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)